Clinical trials
Recurrent WHO Grade 3 Glioma clinical trials
Below are recruiting recurrent who grade 3 glioma clinical trials, each written for real people, not researchers. We’re tracking 97 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07678684RecruitingPhase 2
Study of HF1K16 plus bevacizumab for recurrent glioma
This trial tests a new combination of two drugs, HF1K16 and bevacizumab, for people whose glioma has come back or grown after prior treatment. It aims to see if this combination can help when standard options are no longer working or tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06585527RecruitingPhase 1
TS-2021 for recurrent malignant brain tumors
This trial tests the safety and effectiveness of a new drug called TS-2021 for people whose high-grade brain tumor has come back after initial treatment. It may be an option if you previously had surgery, radiation, or chemotherapy and are now facing a recurrence.
Beijing, Beijing MunicipalityAges 18–65 - NCT04590664RecruitingPhase 1/Phase 2
Verteporfin for recurrent EGFR-mutant glioblastoma
This trial tests verteporfin (Visudyne), given through a vein, for recurrent glioblastoma that has an EGFR mutation or increased EGFR. It aims to shrink or slow the tumor after standard treatment has already been tried.
Atlanta, GeorgiaAges 18 years+ - NCT04299191RecruitingPhase 1/Phase 2
LAM561 for children with advanced brain or solid tumors
This Phase 1/2 study tests a medicine called LAM561 in children whose cancer is advanced and not responding to standard treatment. The goal is to see if the drug is safe and can shrink or control tumors in this setting.
Little Rock, ArkansasAges Up to 18 years - NCT07488754Recruiting
Targeted radiation therapy for new glioma (grade 3-4)
This trial tests a new type of targeted radiation therapy for people with high-grade glioma (grade 3 or 4) that has not progressed after standard treatment. The therapy uses a radioactive substance attached to a protein that targets tumor cells, aiming to deliver radiation directly to the cancer.
Warsaw, PolandAges 18–80 - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT07179328RecruitingPhase 1
Focused ultrasound for glioblastoma during standard chemo
This trial tests whether focused ultrasound can safely open the blood-brain barrier to help your chemotherapy work better. It is for people with glioblastoma who have already completed standard surgery and chemo-radiation and are now on maintenance chemo.
Toronto, OntarioAges 18–85 - NCT03122197RecruitingEarly Phase 1
Letrozole for recurrent high-grade brain tumors
This early-phase study tests letrozole, a hormone-blocking medicine, in adults with recurrent high-grade gliomas. The goal is to see if it can help control the tumor and is safe enough to study further.
Cincinnati, OhioAges 18 years+ - NCT04254419RecruitingPhase 1
Natural killer cell injections in the brain tumor area
This early-phase trial tests injections of lab-grown immune cells directly into (or near) a brain tumor. It aims to see if the treatment is safe and can help control recurrent, progressive, or resistant CNS tumors.
Columbus, OhioAges 1–39 - NCT04794972RecruitingPhase 1
Testing a targeted antibody for advanced solid tumors
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06818331RecruitingPhase 2
Electroacupuncture study for recurring brain cancer
This trial tests if a special type of electroacupuncture can help chemotherapy (paclitaxel) reach the brain more effectively in patients whose high-grade glioma has come back after surgery. The goal is to see if this combination can slow tumor growth.
China, Hangzhou City, Zhejiang ProvinceAges 18–70 - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT05226494RecruitingPhase 1
Test drug fb-PMT in recurrent brain cancer patients
This Phase 1 study tests how safe and tolerable fb-PMT is for people with glioblastoma that has come back. It also helps doctors learn the best way to give it and what side effects to watch for.
New Haven, ConnecticutAges 18 years+ - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT05607407RecruitingPhase 2
Methimazole for progressive glioblastoma after planned surgery
This Phase 2 trial studies whether methimazole, a medicine that affects the thyroid system, can help control progressive glioblastoma (a fast-growing brain tumor) after surgery. It looks at safety and how well the treatment works when given after your surgical plan.
Cleveland, OhioAges 18 years+ - NCT06703255RecruitingPhase 1/Phase 2
Testing HX301 for advanced high-grade glioma
This trial tests an experimental drug called HX301 for people with high-grade gliomas (fast-growing brain tumors). It is for patients whose tumor has come back after temozolomide chemo, or for those with newly diagnosed glioblastoma that has been surgically removed. The study aims to see if HX301 can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06809322RecruitingPhase 3
Vorasidenib maintenance for IDH-mutant astrocytoma after standard treatment
This trial tests whether taking vorasidenib after standard radiation and chemotherapy can help prevent low-grade IDH-mutant astrocytoma from growing back. It is for people who have completed first-line therapy and whose tumors have not progressed.
InnsbruckAges 18 years+ - NCT05190172Recruiting
Proton versus photon radiation for IDH-mutated brain tumors
This trial compares two types of radiation—proton therapy versus photon (standard) therapy—for adults with an IDH-mutated grade 2 or 3 brain tumor. The goal is to see which approach works better and/or causes fewer side effects while treating the tumor.
OsloAges 18–65 - NCT06496971RecruitingPhase 3
Testing focused ultrasound plus Avastin for recurrent glioblastoma
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
TaipeiAges 18–80 - NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+ - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
Los Angeles, CaliforniaAges 18 years+ - NCT06329570RecruitingPhase 1/Phase 2
Bevacizumab with focused ultrasound for recurrent glioblastoma
This trial tests whether adding a focused ultrasound system (NaviFUS) to the drug bevacizumab can help people whose glioblastoma has come back. The treatment aims to deliver the drug more precisely to the brain tumor and potentially improve outcomes.
Charlottesville, VirginiaAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+
Hear when a new Recurrent WHO Grade 3 Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent who grade 3 glioma?
- Yes. Clin2 currently lists 97 recruiting recurrent who grade 3 glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent who grade 3 glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent who grade 3 glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.